A truncated HIV Tat demonstrates potent and specific latency reversal activity
Antimicrobial Agents and Chemotherapy · 2023
DOI: 10.1128/aac.00417-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2023. Verfasst von Ellen Van Gulck und 17 weiteren Autor:innen. Beteiligte Einrichtung: Janssen Infectious Diseases, Janssen Research and Development, A Division of Janssen Pharmaceutica NV , Beerse, Belgium. Hauptthemen laut MEDLINE: HIV Infections, Virus Activation, tat Gene Products, Human Immunodeficiency Virus, HIV-1. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Agentschap Innoveren en Ondernemen, HHS | National Institutes of Health.
Abstract (Originalsprache)
A major barrier to HIV-1 cure is caused by the pool of latently infected CD4 T-cells that persist under combination antiretroviral therapy (cART). This latent reservoir is capable of producing replication-competent infectious viruses once prolonged suppressive cART is withdrawn. Inducing the reactivation of HIV-1 gene expression in T-cells harboring a latent provirus in people living with HIV-1 under cART may result in depletion of this latent reservoir due to cytopathic effects or immune clearance. Studies have investigated molecules that reactivate HIV-1 gene expression, but to date, no latency reversal agent has been identified to eliminate latently infected cells harboring replication-competent HIV in cART-treated individuals. Stochastic fluctuations in HIV-1 tat gene expression have been described and hypothesized to allow the progression into proviral latency. We hypothesized that exposing latently infected CD4+ T-cells to Tat would result in effective latency reversal. Our results indicate the capacity of a truncated Tat protein and mRNA to reactivate HIV-1 in latently infected T-cells ex vivo to a similar degree as the protein kinase C agonist: phorbol 12-myristate 13-acetate, without T-cell activation or any significant transcriptome perturbation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Janssen Infectious Diseases, Janssen Research and Development, A Division of Janssen Pharmaceutica NV , Beerse, Belgium.
- HIV Cure Research Center, Department of Internal Medicine and Pediatrics, Ghent University Hospital, Ghent University , Ghent, Belgium.
- Janssen Infectious Diseases, A Division of Janssen Pharmaceutica NV , Brisbane, California, USA.
- Arcturus Therapeutics, Science Center Drive , San Diego, California, USA.
- Institute of Tropical Medicine , Antwerp, Belgium.
- Faculty of Medicine Sorbonne-University, CIMI-Paris, UPMC/Inserm , Paris, France.
ORCID-Profile: Ellen Van Gulck, Nancie M Archin
Förderung
- NIAID NIH HHS
- Agentschap Innoveren en Ondernemen
- HHS | National Institutes of Health
Zitieren
APA
Van Gulck, E., Pardons, M., Nijs, E., Verheyen, N., Dockx, K., Van Den Eynde, C., Battivelli, E., Vega, J., Florence, E., Autran, B., Archin, N. M., Margolis, D. M., Katlama, C., Hamimi, C., Van Den Wyngaert, I., Eyassu, F., Vandekerckhove, L., & Boden, D. (2023). A truncated HIV Tat demonstrates potent and specific latency reversal activity. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00417-23
Vancouver
Van Gulck E, Pardons M, Nijs E, Verheyen N, Dockx K, Van Den Eynde C, et al. A truncated HIV Tat demonstrates potent and specific latency reversal activity. Antimicrobial Agents and Chemotherapy. 2023. doi:10.1128/aac.00417-23
BibTeX
@article{VanGulck2023,
author = {Van Gulck, Ellen and Pardons, Marion and Nijs, Erik and Verheyen, Nick and Dockx, Koen and Van Den Eynde, Christel and Battivelli, Emilie and Vega, Jerel and Florence, Eric and Autran, Brigitte and Archin, Nancie M and Margolis, David M and Katlama, Christine and Hamimi, Chiraz and Van Den Wyngaert, Ilse and Eyassu, Filmon and Vandekerckhove, Linos and Boden, Daniel},
title = {A truncated HIV Tat demonstrates potent and specific latency reversal activity},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2023},
doi = {10.1128/aac.00417-23}
}
EUVIMED